298
Participants
Start Date
January 31, 2014
Primary Completion Date
June 30, 2014
Study Completion Date
June 30, 2014
PG324 Ophthalmic Solution 0.01%
1 drop in the evening (PM), once daily (QD), both eyes (OU)
PG324 Ophthalmic Solution 0.02%
1 drop in the evening (PM), once daily (QD), both eyes (OU)
Netarsudil (AR-13324) Ophthalmic Solution 0.02%
1 drop in the evening (PM), once daily (QD), both eyes (OU)
Latanoprost Ophthalmic Solution 0.005%
1 drop in the evening (PM), once daily (QD), both eyes (OU)
Ophthalmic Consultants of Long Island, Lynbrook
Rochester Ophthalmological Group, Rochester
Seidenberg Protzko Eye Associates, Havre de Grace
Virginia Eye Consultants, Norfolk
Michael E. Tepedino, M.D., High Point
Charlotte Eye Ear Nose & Throat Associates, P.A., Belmont
Coastal Research Associates, LLC, Roswell
Clayton Eye Center, Morrow
Taustine Eye Center, Louisville
Great Lakes Eye Care, Saint Joseph
Comprehensive Eye Care, St Louis
Bradley Kwapiszeski, MD, Shawnee Mission
The Eye Institute, Tulsa
Glaucoma Associates of Texas - Dallas Office, Dallas
Medical Center Ophthalmology Associates, San Antonio
Texan Eye, Austin
Cataract & Glaucoma Center, El Paso
Stacy R. Smith, M.D., Salt Lake City
United Medical Research Institute, Inglewood
Kenneth Sall, M.D., Artesia
Centre For Health Care, Poway
Aesthetic Eye Care Institute, Newport Beach
Bacharach practice, Petaluma
Lead Sponsor
Aerie Pharmaceuticals
INDUSTRY